Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen.
Miyuki Kubota, Motoko Kawashima, Sachiko Inoue, Toshihiro Imada, Shigeru Nakamura, Shunsuke Kubota, Mitsuhiro Watanabe, Ryo Takemura, Kazuo Tsubota · Scientific reports · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The researchers found that administering a persistent H₂-generating supplement increased the human exhaled H₂ concentration (p < 0.01) and improved tear stability (p < 0.01) and dry eye symptoms (p < 0.05) significantly. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 10 participants. The researchers found that administering a persistent H₂-generating supplement increased the human exhaled H₂ concentration (p < 0.01) and improved tear stability (p < 0.01) and dry eye symptoms (p < 0.05) significantly.
What the Researchers Studied
The researchers studied 10 participants. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Molecular hydrogen (H₂) is known to be effective against various diseases; therefore, the researchers aimed to elucidate the effects of H₂ on tear dynamics and the treatment of dry eye disease. The researchers found that administering a persistent H₂-generating supplement increased the human exhaled H₂ concentration (p < 0.01) and improved tear stability (p < 0.01) and dry eye symptoms (p < 0.05) significantly. H₂ significantly increased tear secretion in healthy mice (p < 0.05) and significantly suppressed tear reduction in a murine dry eye model (p = 0.007).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 10 participants. The study used a human clinical study.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.